These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 10393445)
1. Autoantibodies against oxidatively modified low-density lipoprotein in patients with Behçet's disease. Orem A; Cimşit G; Değer O; Vanizor B; Karahan SC Dermatology; 1999; 198(3):243-6. PubMed ID: 10393445 [TBL] [Abstract][Full Text] [Related]
2. The evaluation of autoantibodies against oxidatively modified low-density lipoprotein (LDL), susceptibility of LDL to oxidation, serum lipids and lipid hydroperoxide levels, total antioxidant status, antioxidant enzyme activities, and endothelial dysfunction in patients with Behçet's disease. Orem A; Yandi YE; Vanizor B; Cimşit G; Uydu HA; Malkoç M Clin Biochem; 2002 May; 35(3):217-24. PubMed ID: 12074830 [TBL] [Abstract][Full Text] [Related]
3. Changes of autoantibodies against oxidatively modified low density lipoproteins during long-term LDL-apheresis. Turk Z; Mrzljak V; Turk N; Metelko Z Diabetes Nutr Metab; 1999 Dec; 12(6):413-7. PubMed ID: 10782563 [TBL] [Abstract][Full Text] [Related]
4. Patients with early rheumatoid arthritis exhibit elevated autoantibody titers against mildly oxidized low-density lipoprotein and exhibit decreased activity of the lipoprotein-associated phospholipase A2. Lourida ES; Georgiadis AN; Papavasiliou EC; Papathanasiou AI; Drosos AA; Tselepis AD Arthritis Res Ther; 2007; 9(1):R19. PubMed ID: 17326817 [TBL] [Abstract][Full Text] [Related]
5. The low-density lipoprotein (LDL)-associated PAF-acetylhydrolase activity and the extent of LDL oxidation are important determinants of the autoantibody titers against oxidized LDL in patients with coronary artery disease. Lourida ES; Papathanasiou AI; Goudevenos JA; Tselepis AD Prostaglandins Leukot Essent Fatty Acids; 2006 Aug; 75(2):117-26. PubMed ID: 16843649 [TBL] [Abstract][Full Text] [Related]
6. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients. Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071 [TBL] [Abstract][Full Text] [Related]
7. The significance of autoantibodies against oxidatively modified low-density lipoprotein (LDL) in patients with psoriasis. Orem A; Cimşit G; Değer O; Orem C; Vanizor B Clin Chim Acta; 1999 Jun; 284(1):81-8. PubMed ID: 10437645 [TBL] [Abstract][Full Text] [Related]
9. The effects of metabolic control on oxidized low-density lipoprotein antibodies in children and adolescents with type 1 diabetes mellitus. Kara C; Cetinkaya S; Sezgin N; Kinik ST Pediatr Diabetes; 2008 Feb; 9(1):17-22. PubMed ID: 18211632 [TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein E polymorphism and lipoprotein compositions in patients with Behçet's disease. Tursen U; Eskandari G; Kaya TI; Tamer L; Ikizoglu G; Atik U Int J Dermatol; 2004 Dec; 43(12):900-3. PubMed ID: 15569012 [TBL] [Abstract][Full Text] [Related]
11. Serum autoantibodies against human oxidized low-density lipoproteins are inversely associated with severity of coronary stenotic lesions calculated by Gensini score. Che J; Li G; Wang W; Li Q; Liu H; Chen K; Liu T Cardiol J; 2011; 18(4):364-70. PubMed ID: 21769816 [TBL] [Abstract][Full Text] [Related]
12. Autoantibodies to malondialdehyde-modified low-density lipoprotein in patients with angiographically confirmed coronary artery disease. McDowell A; Young IS; Wisdom GB J Pharm Pharmacol; 2002 Dec; 54(12):1651-7. PubMed ID: 12542895 [TBL] [Abstract][Full Text] [Related]
13. Circulating oxidized low density lipoprotein, autoantibodies against them and homocysteine serum levels in diagnosis and estimation of severity of coronary artery disease. Faviou E; Vourli G; Nounopoulos C; Zachari A; Dionyssiou-Asteriou A Free Radic Res; 2005 Apr; 39(4):419-29. PubMed ID: 16028367 [TBL] [Abstract][Full Text] [Related]
14. Association of serum MMP-9 with autoantibodies against oxidized LDL. Kalela A; Koivu TA; Höyhtyä M; Jaakkola O; Lehtimäki T; Sillanaukee P; Nikkari ST Atherosclerosis; 2002 Jan; 160(1):161-5. PubMed ID: 11755934 [TBL] [Abstract][Full Text] [Related]
15. High circulating autoantibodies against human oxidized low-density lipoprotein are related to stable and lower titers to unstable clinical situation. Santos AO; Fonseca FA; Fischer SM; Monteiro CM; Brandão SA; Póvoa RM; Bombig MT; Carvalho AC; Monteiro AM; Ramos E; Gidlund M; Figueiredo Neto AM; Izar MC Clin Chim Acta; 2009 Aug; 406(1-2):113-8. PubMed ID: 19523463 [TBL] [Abstract][Full Text] [Related]
16. Detection of oxidized low-density lipoproteins in gingival crevicular fluid from dental patients. Sakiyama Y; Kato R; Inoue S; Suzuki K; Itabe H; Yamamoto M J Periodontal Res; 2010 Apr; 45(2):216-22. PubMed ID: 19778326 [TBL] [Abstract][Full Text] [Related]
17. Serum Lipid, Lipoprotein and Oxidatively Modified Low Density Lipoprotein Levels in Active or Inactive Patients with Behçet's Disease. Cimen F; Yildirmak ST; Ergen A; Cakmak M; Dogan S; Yenice N; Sezgin F Indian J Dermatol; 2012 Mar; 57(2):97-101. PubMed ID: 22615503 [TBL] [Abstract][Full Text] [Related]
18. Antibodies against human oxidized low-density lipoprotein (LDL) as markers for human plasma modified lipoproteins. Radulescu L; Stancu C; Antohe F Med Sci Monit; 2004 Jul; 10(7):BR207-14. PubMed ID: 15232494 [TBL] [Abstract][Full Text] [Related]
20. Is plasma oxidized low-density lipoprotein, measured with the widely used antibody 4E6, an independent predictor of coronary heart disease among U.S. men and women? Wu T; Willett WC; Rifai N; Shai I; Manson JE; Rimm EB J Am Coll Cardiol; 2006 Sep; 48(5):973-9. PubMed ID: 16949489 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]